Optimizing a management strategy for patients with secondary AA amyloidosis

DOI: https://doi.org/10.29296/25877305-2019-05-01
Download full text PDF
Issue: 
5
Year: 
2019

V. Rameev, Candidate of Medical Sciences; Professor L. Kozlovskaya, MD; A. Rameeva; P. Tao I.M. Sechenov First Moscow State Medical University (Sechenov University)

Analysis of the data obtained in a large group of patients could present the current structure of the causes and clinical manifestations of AA amyloidosis. By using the results of estimating the levels of SAA and S100A12, the authors consider the fundamental features of amyloidogenesis in the presence of chronic inflammation, discuss the main features of the etiology and course of amyloidosis, and propose approaches to optimizing a management strategy for patients.
Keywords: 
AA amyloidosis
SAA
rheumatoid arthritis
autoinflammatory diseases
periodic disease
Castleman disease
S100A12

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Kyle R. Amyloidosis: a convoluted story // Br. J. Haematol. – 2001; 114: 5295–38.
  2. Hans L., Nienhuis J., Hazenberg B. The Prevalence and Management of Systemic Amyloidosis in Western Countries // Kidney Dis. – 2016; 2: 10–9.
  3. Hermodson M., Kuhn R., Walsh K. et al. Amino acid sequence of monkey amyloid protein A // Biochemistry. – 1972; 11: 2934–8.
  4. Glenner G., Terry W., Harada M. et al. Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses // Science. – 1971; 172: 1150–1.
  5. Sipe J., Benson M., Buxbaum J. et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines // Amyloid. – 2016; 23 (4): 209–13.
  6. Serov V.V., Shamov I.A. Amiloidoz / M.: Meditsina, 1977; 288 s. [Serov V.V., Shamov I.A. Amiloidoz / M.: Meditsina, 1977; 288 s. (in Russ.)].
  7. Muhin N.A. Amiloidoz pochek: voprosy kliniki i patogeneza. Avtoref. diss. … d-ra med. nauk. M., 1981; s. 41 [Mukhin N.A. Amiloidoz pochek: voprosy kliniki i patogeneza. Avtoref. diss. … d-ra med. nauk. M., 1981; s. 41 (in Russ.)].
  8. Lachmann H., Goodman H., Gilbertson J. et al. Natural history and outcome in systemic AA amyloidosis // N. Engl. J. Med. – 2007; 356 (23): 2361–71.
  9. Pinney J., Smith C., Taube J. et al. Systemic amyloidosis in England: an epidemiological study // Br. J. Haematol. – 2013; 161: 525–32.
  10. Ajvazjan A.A. Periodicheskaja bolezn' / Erevan: Ajastan, 1982; 215 s. [Aivazyan A.A. Periodicheskaya bolezn’ / Erevan: Aiastan, 1982; 215 s. (in Russ.)].
  11. Piram M. et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes // Ann. Rheum. Dis. – 2014; 73 (12): 2168–73.
  12. Kuemmerle-Deschner J. et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome // Arthritis Rheum. – 2011; 63 (3): 840–9.
  13. van der Linden M., Knevel R., Huizinga T. et al. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria // Arthritis Rheum. – 2011; 63 (1): 37–42.
  14. Mukhtyar C. et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) // Ann. Rheum. Dis. – 2009; 68 (12): 1827–32.
  15. Martins N., Furtado G., Campos M. et al. Exercise and ankylosing spondylitis with New York modified criteria: a systematic review of controlled trials with meta-analysis // Acta Reumatol Port. – 2014; 39 (4): 298–308.
  16. Direskeneli H., Gül A. ISBD basic research perspectives. A preliminary «outline « for basic research workshop studies // Adv. Exp. Med. Biol. – 2003; 528: 293–9.
  17. Mourgues C., Pereira B., Vorilhon P. et al. 2012 American guidelines for the management of gout as seen by general practitioners. Comment on «GOSPEL 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century – comparison with 2006 EULAR Recommendations // Joint Bone Spine. – 2018; 1: 1297–319.